Two doses of targeted therapy plus immunotherapy for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing two different doses of a targeted pill (famitinib) combined with an immunotherapy drug (camrelizumab) for cervical cancer that has come back or spread and has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer that has returned or spread, and it cannot be cured with surgery, radiation, or chemo.
- You have already had at least one round of platinum-based chemotherapy, but no more than two prior treatments.
- You have never been treated with bevacizumab (a blood vessel blocker).
- You are able to have a biopsy to test for PD-L1 (a protein that helps some treatments work).
- You are in good general health, with an ECOG score of 0 or 1 (meaning you are fully active or only slightly limited).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well camrelizumab or famitinib (alone or with other treatments) work for cervical cancer. It aims to gather real-world information to help guide treatment decisions.
This study tests a new combination of two drugs for cervical cancer that has returned or spread and did not get better with platinum-based chemotherapy. It aims to see if the combination works better than the standard treatment options.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This study tests a combination of two drugs (camrelizumab and famitinib) given after surgery for early-stage cervical cancer. The goal is to see if this treatment helps keep the cancer from returning. It is for people who have not had any other cancer treatment yet.
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.